Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 23.85
0.00 (0.00%)
Nov 10, 2026, 1:30 PM CST
Excelsior Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 959.88 | 898.26 | 861.91 | 771.56 | 671.76 | 1,338 | |
Revenue Growth | 11.64% | 4.22% | 11.71% | 14.86% | -49.81% | -7.29% |
Cost of Revenue | 593.16 | 538.1 | 479.82 | 464.63 | 384.59 | 1,045 |
Gross Profit | 366.73 | 360.17 | 382.1 | 306.93 | 287.17 | 293.35 |
Selling, General & Admin | 454.17 | 438.24 | 377.21 | 324.57 | 277.82 | 241.65 |
Research & Development | 88 | 96.09 | 83.62 | 62.51 | 42.32 | 56 |
Operating Expenses | 545.96 | 531.77 | 463.07 | 388.06 | 316.47 | 302.12 |
Operating Income | -179.24 | -171.6 | -80.97 | -81.13 | -29.29 | -8.77 |
Interest Expense | -9.94 | -7.77 | -8.02 | -6.37 | -4.35 | -4.54 |
Interest & Investment Income | 1.06 | 1.26 | 3.42 | 5.24 | 4.17 | 0.41 |
Earnings From Equity Investments | 2.19 | 2.18 | 0.25 | - | - | - |
Currency Exchange Gain (Loss) | -2.53 | -2.53 | -4.94 | -1.55 | -1.28 | 1.81 |
Other Non Operating Income (Expenses) | 15.86 | 6.16 | 2.87 | 1.86 | 3.68 | 0.9 |
EBT Excluding Unusual Items | -172.6 | -172.3 | -87.39 | -81.95 | -27.06 | -10.19 |
Gain (Loss) on Sale of Assets | -0.65 | -0.65 | - | - | - | - |
Other Unusual Items | 0.6 | 0.6 | 0 | - | 1.07 | 0.16 |
Pretax Income | -172.64 | -172.34 | -87.39 | -81.95 | -25.99 | -10.03 |
Income Tax Expense | 12.06 | 10.83 | 11.32 | 9.06 | 7.76 | 5.62 |
Net Income | -184.7 | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 |
Net Income to Common | -184.7 | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 46 | 46 | 46 | 46 | 46 | 47 |
Shares Outstanding (Diluted) | 46 | 46 | 46 | 46 | 46 | 47 |
Shares Change | 0.60% | 0.12% | 0.42% | 0.15% | -1.42% | -5.56% |
EPS (Basic) | -3.98 | -3.97 | -2.14 | -1.98 | -0.74 | -0.34 |
EPS (Diluted) | -3.98 | -3.97 | -2.14 | -1.98 | -0.74 | -0.34 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -101.44 | -175.67 | -356.95 | -170.41 | -2.3 | 52.95 |
Free Cash Flow Per Share | -2.19 | -3.81 | -7.74 | -3.71 | -0.05 | 1.14 |
Gross Margin | 38.20% | 40.10% | 44.33% | 39.78% | 42.75% | 21.92% |
Operating Margin | -18.67% | -19.10% | -9.40% | -10.51% | -4.36% | -0.66% |
Profit Margin | -19.24% | -20.39% | -11.45% | -11.80% | -5.03% | -1.17% |
Free Cash Flow Margin | -10.57% | -19.56% | -41.41% | -22.09% | -0.34% | 3.96% |
EBITDA | -162.37 | -152.62 | -65.64 | -69.31 | -16.41 | 6.39 |
EBITDA Margin | -16.91% | -16.99% | -7.62% | -8.98% | -2.44% | 0.48% |
D&A For EBITDA | 16.87 | 18.98 | 15.33 | 11.82 | 12.88 | 15.15 |
EBIT | -179.24 | -171.6 | -80.97 | -81.13 | -29.29 | -8.77 |
EBIT Margin | -18.67% | -19.10% | -9.40% | -10.51% | -4.36% | -0.66% |